New PET tracer could spot hidden cancers

NCT ID NCT04459273

Ongoing Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can help detect and understand different cancers better than current methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium Ga 68 FAPi-46 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a new imaging method to better detect and understand many types of cancer, potentially improving diagnosis and treatment planning.
What could go wrong: This is a very early, small study (26 people) focused on imaging, not treatment. The tracer may not work well for all cancers, and results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland cancer brain cancer cancer cancer of unknown primary site cervical carcinoma cholangiocarcinoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm hepatocellular carcinoma Neoplasms, Unknown Primary neuroendocrine neoplasm pleural cancer skin cancer skin neoplasm testicular cancer thymus cancer Thymus Neoplasms thyroid gland carcinoma Thyroid Neoplasms transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CARCINOMA CANCER OF UNKNOWN PRIMARY SITE CERVICAL CARCINOMA CHOLANGIOCARCINOMA HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM HEPATOCELLULAR CARCINOMA MALIGNANT ADRENAL GLAND NEOPLASM MALIGNANT BRAIN NEOPLASM MALIGNANT PLEURAL NEOPLASM MALIGNANT SKIN NEOPLASM MALIGNANT SOLID NEOPLASM MALIGNANT TESTICULAR NEOPLASM MALIGNANT THYMUS NEOPLASM NEUROENDOCRINE NEOPLASM THYROID GLAND CARCINOMA UROTHELIAL CARCINOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.